FOSTER CITY, Calif., April 17, 2026

Gilead Sciences, Inc. has announced that it has obtained all required regulatory approvals for its planned acquisition of Arcellx, marking a major milestone in advancing its cell therapy and oncology pipeline strategy. The company also confirmed an extension of its tender offer deadline to April 27, 2026, as it moves closer to completing the transaction. This development underscores Gilead’s continued focus on expanding its next-generation cancer therapies portfolio, particularly in the field of CAR-T cell therapy.

Regulatory Clearances Enable Transaction Progression

The acquisition has successfully passed all necessary regulatory reviews, including approvals from the Australian Competition and Consumer Commission (ACCC) and Austrian authorities. The ACCC has confirmed that the transaction may proceed, subject to a standard 14-day waiting period, after which the “Regulatory Approvals Condition” will be fully satisfied.

With these approvals secured, Gilead has extended its tender offer to allow additional time for shareholders to participate. The offer includes $115 per share in cash plus a contingent value right (CVR), which could provide an additional $5 payment based on future commercial milestones tied to Arcellx’s lead product candidate.

As of mid-April 2026, approximately 17.5% of outstanding shares had been tendered, reflecting early investor participation while the company works toward meeting the required majority ownership threshold to complete the deal.

Advertisement

cGxPJobs Banner

Strategic Focus on CAR-T and Oncology Innovation

The acquisition of Arcellx aligns with Gilead’s broader strategy to strengthen its leadership in cell therapy and oncology innovation, particularly through its Kite Pharma division. Arcellx’s lead asset, anitocabtagene autoleucel (anito-cel), is a CAR-T therapy targeting multiple myeloma, with significant commercial potential.

The inclusion of a contingent value right tied to cumulative global sales exceeding $6 billion by 2029 reflects strong confidence in the long-term value of this therapy. If successful, the acquisition could significantly enhance Gilead’s position in the rapidly growing CAR-T therapy market, which is expected to play a central role in future cancer treatment paradigms.

This move is also consistent with Gilead’s commitment to long-term investment in innovation, including its previously announced $32 billion U.S. investment initiative, aimed at accelerating drug discovery, expanding manufacturing capabilities, and improving global health outcomes.

Advancing Toward Deal Completion and Market Impact

The transaction remains subject to customary closing conditions, including achieving a majority of tendered shares. Once completed, the acquisition is expected to accelerate Gilead’s oncology pipeline, enabling faster development and commercialization of innovative therapies for patients with life-threatening cancers.

The deal also highlights ongoing consolidation within the biopharmaceutical industry, where large companies are increasingly acquiring specialized biotech firms to gain access to cutting-edge technologies and clinical-stage assets. Such strategic acquisitions are reshaping the competitive landscape and driving innovation in precision medicine and advanced therapeutics.

The completion of regulatory approvals for the Gilead–Arcellx acquisition represents a critical step toward strengthening Gilead’s oncology and cell therapy capabilities. With the transaction nearing completion, the company is poised to expand its impact in next-generation cancer treatments, reinforcing its position as a global leader in biopharmaceutical innovation and strategic growth.

Source: Gilead Sciences, Arcellx press release